The public interest group Judicial Watch recently obtained more than 8,000 reports, under the US Freedom of Information law, of adverse events in girls and young women after they were injected with the HPV vaccine Gardasil. The reports reveal everything from massive wart outbreaks to seizures, paralysis and death. Ten deaths have been reported since September 2007, bringing the total to 18 since the vaccine was approved for use in 2006.
In this year there have been 140 reported “serious” complications, 27 of which were categorized as “life-threatening,” as well as ten spontaneous abortions and six cases of Guillain-Barré Syndrome, a very rare (1 in 100,000 in a healthy population) immune response to foreign antigens such as infectious agents or vaccines, that paralyzes the afflicted person.
My Take?
I agree with Judicial Watch President Tom Fitton, who says, “Given all the questions about Gardasil, the best public health policy would be to reevaluate its safety and to prohibit its distribution to minors. In the least, governments should rethink any efforts to mandate or promote this vaccine for children.”
LifeNews.com quotes Gwen Landolt, national vice-president of REAL Women of Canada, who has commented on the lack of proper testing before Gardasil was pushed through the approval process and the consequences of its widespread use.
“The long-term consequences of Gardasil are not known.  The manufacturer admits this and agrees it does not know its effect on young girls’ cancer risk, on their immunity system, on their reproductive system, or its genetic effects.  In due course, we will know this, possibly in twenty or thirty years from now when these young girls, the innocent subjects of the Gardasil experiment have become grown women and then report the consequences of their having taken the medication in their childhood on medical advice.”
The Wall Street Journal has reported that Merck & Co.’s shares dropped 4.8% triggering a sell-off of the company’s stock and a downgrade of their rating on the New York Stock Exchange.